Drugs / Fenoverine
Fenoverine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01507922 | Dec 2011 → Mar 2013 | irritable bowel syndrome | Bukwang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fenoverine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01507922 ↗ |
| Known as | Fenoverina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1512949 ↗ |
| Known as | Spasmopriv | ChEMBL registry synonym — accepted as the source's own label CHEMBL1512949 ↗ |
| Modality | Small molecule | — CHEMBL1512949 ↗ |
| Route | Oral | “Fenoverine and Trimebutine will be administered orally for 8 weeks” NCT01507922 ↗ |